Oesophageal Adenocarcinoma Clinical Trial
Official title:
Effect of Neoadjuvant Chemotherapy on Muscle Mass and Peri-operative Cardiorespiratory Performance in Patients Undergoing Oesophageal Cancer- a Pilot Study
Curative treatment for oesophageal cancer involves undertaking chemotherapy followed by an operation to remove the tumour. Chemotherapy has several effects upon the body, including effects upon the systems that control the creation and breakdown of muscle. We aim to review these effects by recording changes in the amount of exercise patients are able to undertake after chemotherapy and reviewing changes in muscle mass.
We aim to review the effects of chemotherapy on skeletal muscle mass and cardio-respiratory performance in patients with oesophageal adenocarcinoma. All patients will be assessed by a Consultant Anaesthetist and a medical member of the Research team before commencing chemotherapy and after finishing their course. These assessments include a nutritional assessment, performance status assessments, blood assays, dual energy X-ray absorptiometry (DEXA) scans, cardio-pulmonary exercise (CPEX) testing and a muscle biopsy. ;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02962219 -
Exercise Prior to Oesophagectomy
|
N/A | |
Recruiting |
NCT03626610 -
Prehabilitation of Patients With oEsophageal Malignancy Undergoing Peri-operative Treatment
|
N/A | |
Suspended |
NCT05135845 -
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03399071 -
Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04554771 -
Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy
|
Phase 2 | |
Active, not recruiting |
NCT05104567 -
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
|
Phase 2 | |
Completed |
NCT03641547 -
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
|
Phase 1 | |
Recruiting |
NCT06289374 -
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
|